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Abstract
Metaplastic breast cancers (MBC) are aggressive, chemo-
resistant tumors characterized by lineage plasticity. To
advance understanding of their pathogenesis and relatedness
to other breast cancer subtypes, 28 MBCs were compared with
common breast cancers using comparative genomic hybrid-
ization, transcriptional profiling, and reverse-phase protein
arrays and by sequencing for common breast cancer muta-
tions. MBCs showed unique DNA copy number aberrations
compared with common breast cancers. PIK3CA mutations
were detected in 9 of 19 MBCs (47.4%) versus 80 of 232
hormone receptor–positive cancers (34.5%; P = 0.32), 17 of 75
HER-2–positive samples (22.7%; P = 0.04), 20 of 240 basal-like
cancers (8.3%; P < 0.0001), and 0 of 14 claudin-low tumors
(P = 0.004). Of 7 phosphatidylinositol 3-kinase/AKT pathway
phosphorylation sites, 6 were more highly phosphorylated in
MBCs than in other breast tumor subtypes. The majority
of MBCs displayed mRNA profiles different from those of the
most common, including basal-like cancers. By transcriptional
profiling, MBCs and the recently identified claudin-low breast
cancer subset constitute related receptor-negative subgroups
characterized by low expression of GATA3-regulated genes and
of genes responsible for cell-cell adhesion with enrichment for
markers linked to stem cell function and epithelial-to-
mesenchymal transition (EMT). In contrast to other breast
cancers, claudin-low tumors and most MBCs showed a
significant similarity to a ‘‘tumorigenic’’ signature defined
using CD44+/CD24 breast tumor–initiating stem cell–like
cells. MBCs and claudin-low tumors are thus enriched in EMT
and stem cell–like features, andmay arise from an earlier, more
chemoresistant breast epithelial precursor than basal-like or
luminal cancers. PIK3CA mutations, EMT, and stem cell-like
characteristics likely contribute to the poor outcomes of
MBC and suggest novel therapeutic targets. [Cancer Res
2009;69(10):4116–24]
Introduction
Metaplastic breast cancers (MBC) are aggressive estrogen re-
ceptor-a–negative, progesterone receptor-negative, HER-2–negative
(triple-negative) tumors characterized by mesenchymal/sarcoma-
toid and/or squamous metaplasia of malignant breast epithelium
(1–7). Because of limited understanding of their pathogenesis,
MBCs are treated in the same fashion as basal-like or triple re-
ceptor-negative ductal cancers. However, whereas neoadjuvant che-
motherapy is associated with high pathologic complete response
rates in basal-like carcinomas, MBCs are usually chemoresistant (2).
Transcriptional profiling has defined breast cancer subtypes
(8, 9). The origin of luminal A and B tumors appears to be the
mammary duct luminal epithelium with concomitant hormone
receptor expression. Elevated HER-2 expression defines a subgroup
with a poor prognosis; however, the responsiveness of this sub-
group to trastuzumab improves outcomes (10). In contrast, basal-
like cancers likely represent multiple different subtypes arising
from distinct precursor cells from those of other cancers. Some
basal-like breast cancers likely arise from mammary myoepithelial
cells. To date, basal-like cancers have not presented specific ther-
apy targets.
As MBCs are triple-negative, they are distinct from luminal and
HER-2-amplified cancers. As they express some markers associated
with basal-like cancers (e.g., epidermal growth factor receptor
and cytokeratins 5/6), MBCs are proposed to represent a form
of basal-like breast cancer. However, distinct clinical features such
as chemoresistance suggest that MBCs may represent a unique
subtype (2, 3).
We applied an integrated genomic-proteomic approach to
determine mechanisms underlying metaplastic carcinogenesis
and MBC chemoresistance along with the relatedness of MBCs to
known breast cancer subtypes. Most MBCs showed a unique
molecular profile and form a distinct subtype most closely related
to a novel subset of receptor-negative breast cancers (claudin-low)
characterized by loss of genes involved in cell-cell adhesion.
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
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An enrichment for stem cell-like and epithelial-to-mesenchymal
transition (EMT) markers in MBCs (and claudin-low tumors) along
with frequent genomic aberrations that activate the phosphatidy-
linositol 3-kinase (PI3K)/AKT pathway suggest reasons for MBC
chemoresistance and that MBCs and claudin-low tumors may arise
from more immature precursor cells than other breast cancers.
Materials and Methods
Human tumors. Twenty-eight frozen grade 3 MBCs with sarcomatoid
(19) or squamous (9) metaplasia were obtained from the Breast Tumor
Bank at The University of Texas M. D. Anderson Cancer Center (MDACC)
and from a collaborator in Valencia (A.L.). The diagnosis was reconfirmed
by pathologists at MDACC (M.Z.G. and S.K.; refs. 2, 3). Frozen tissue
was used for DNA extraction (28 tumors) and, where adequate frozen
tumor tissue remained, for RNA and protein extraction (16 MDACC tumors;
ref. 11).
Three tumor cohorts were used for comparison with MBCs (Supple-
mentary Fig. S1). The first cohort, used for comparison of mutation
frequency (547 tumors) and functional proteomic profiles (693), was
composed of 693 frozen primary breast tumors obtained under institutional
review board-approved protocols from MDACC. These tumors were sub-
divided into clinically defined subtypes as described previously (Table 1;
ref. 12).
A second cohort of 145 primary breast tumors was used for comparison
with MBC gene copy number profiles herein (13, 14). A third cohort (Line-
berger Comprehensive Cancer Center) of 184 breast tumors and 9 normal
breast tissues was used for comparison with MBC transcriptional profiles
(8, 9, 15). There were no statistically significant differences in the proportion
of patients with tumors of different stages between the cohorts.
Comparative genomic hybridization. Comparative genomic hybrid-
ization profiles from the 28 MBCs were generated at Lawrence Berkeley
National Laboratory using single nucleotide polymorphism (SNP)-based
GeneChip Human Mapping 50K Sty arrays (Affymetrix) and compared with
BAC-comparative genomic hybridization profiles of primary breast tumors
previously generated and processed (J.F.) at Lawrence Berkeley National
Laboratory using HumArray1.14/HumArray2.0 (13, 14, 16–18). MBC 50K
data are available.12
For comparison with Lawrence Berkeley National Laboratory tumors, the
28 MBC SNP chips were mapped to BAC resolution. This approach has been
validated by comparing data derived using both platforms to analyze breast
cancer cell lines (data not shown). Lawrence Berkeley National Laboratory
tumors were remapped to the May04 freeze from University of California-
Santa Cruz and regions around each BAC clone were defined as within a
half distance to each neighboring clone or to the beginning or end of the
chromosome if telomeric. A median expression value was then obtained for
SNPs in each BAC region. Missing values were assigned if <5 SNPs mapped
to a particular region. Each array was recentered to have a median of 0. The
resulting values were segmented using circular binary segmentation (CBS)
followed by a merge-level procedure to combine segmented levels across
the genome. Each missing value was assigned the value of its corresponding
segment. Gain/loss events and fraction of genome altered were calculated.
After this resolution reduction (median, 18 SNPs/BAC; mean, 30), the mean
variability estimate was 0.25. Similar analyses beginning with the CBS steps
were done on the original dChip processed data. We used a Fisher’s test
to measure the difference in copy number at probes on each side of
genes encoding PI3K/AKT pathway components. These P values were used
to fit a h-uniform mixture model to determine significance at a given false
discovery rate.
To directly compare the 50K SNP and older BAC platforms, DNA ex-
tracted from five MBCs was also run using the BAC platform. This con-
firmed a high concordance for the matched data derived from the two
platforms (data not shown).
Detection of mutations. DNA was extracted from 547 MDACC breast
tumors along with 14 Lineberger Comprehensive Cancer Center claudin-low
breast tumors and 19 MBCs with sufficient remaining DNA for mutation
detection (9, 11, 12). Following whole-genome amplification, p53/PTEN
genes were resequenced (19). CTNNB1 exon 3 (the most common site of
mutations) was amplified from genomic DNA using a forward primer
located at the 5¶ portion and a reverse primer at the 3¶ end of the exon. A
tumor sample with a known CTNNB1 mutation was amplified and
sequenced in parallel with tumor samples as a positive control. A SNP-
based approach (Sequenom MassArray) was used to detect mutations in
PIK3CA, KRAS , and E17K mutations in the AKT1/2/3 genes (12, 20). This
approach is unsuitable for detection of mutations that are not ‘‘hotspot’’
mutations but is particularly suitable to mutation detection in breast cancer
where stromal ‘‘contamination’’ is prevalent (21).
Reverse-phase protein array. Reverse-phase protein array was applied
with the antibodies in Supplementary Table S1 to compare PI3K/AKT and
mitogen-activated protein kinase (MAPK) pathway activation in protein
lysates derived from 16 MBCs versus 693 common breast cancers
(Supplementary Table S2; refs. 22–25). The expression of each antibody in
a sample was corrected for protein loading using the average expression
levels of all probed proteins. Antibodies were obtained from SDI (YB1),
Epitomics, Inc. (p70S6K, PR), Lab Vision Corporation (ERa), Santa Cruz
Biotechnology (CCNDI, CCNEI, EGFR, GSK3, p27), Upstate Biotechnology
(Src) and Cell Signaling Technology, Inc.
Transcriptional profiling. Total RNA was isolated by phenol-chloro-
form extraction (Trizol, Life Technologies), and mRNA was purified by
either magnetic separation using Dynabeads (Dynal) or the Invitrogen
FastTrack 2.0 Kit. Twelve of 16 MBC RNA samples with RNA integrity
numbers > 6 were assayed on Agilent oligomicroarrays at Lineberger Com-
prehensive Cancer Center and compared with a published Agilent micro-
array data set also previously assayed and processed (C.M.P.) at Lineberger
Comprehensive Cancer Center (8, 9, 15). The microarray and clinical data
are available at University of North Carolina Microarray Database and in the
Gene Expression Omnibus (GSE10885). Expression Analysis Systematic
Explorer was applied to perform functional analysis of gene lists.
Mapping gene expression onto regions of MBC copy number
change. Using a Significance Analysis of Microarray (SAM)-defined list of
MBC-defining genes, we determined the chromosomal location of each
gene to link with the comparative genomic hybridization data. Probes
with an undefined chromosomal position were discarded from further
analyses. CBS was applied to the preprocessed MBC copy number data to
determine breakpoints for aberrations (26). The CBS calls made were as
follows: class.segment <- segment (class.cna, a = 0.05, p.method = ‘‘perm,’’
nperm = 1,000, trim = 0.05, undo.splits = ‘‘sdundo,’’ undo.SD = 2, verbose = 2).
Using CBS output, a plot of segment intensities versus segment markers
was used to determine an intensity boundary threshold of 0.12. Segments
with intensity values beyond this threshold were flagged as gained or
lost based on the sign of intensity and parsed from the original CBS output.
By applying a customized R script to this output, segments from each
sample were collated and regions were assigned that had varying levels of
overlap between the MBC patients. Cutoffs were made for regions with
aberrations in z1 of 3 of MBCs tested. SAM genes with chromosomal
locations that were contained within these gains and losses were
determined and plotted.
Comparison of the MBC and claudin-low transcriptional profiles
with a CD44+/CD24/low breast cancer cell profile. We compared
breast tumor transcriptional signatures with a ‘‘tumorigenic’’ signature13 that
was derived by comparing gene expression profiles of flow-sorted CD44+/
CD24/low cancer cells with profiles of all other sorted cells (CD44/CD24+
and CD44/CD24 combined). For each tumor, a ‘‘R value’’ was derived in
relation to the ‘‘tumorigenic’’ signature, which was defined as the Pearson’s
correlation between the ‘‘tumorigenic’’ gene signature pattern (using ‘‘1’’ and
12 ftp://beamish.lbl.gov/njwang/ 13 Creighton et al., submitted for publication.
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‘‘-1’’ for up and down, respectively) and tumor expression values. Tumors
with high R values would tend to have both high expression of many of the
genes high in ‘‘tumorigenic’’ cells and low expression of many of the genes
low in ‘‘tumorigenic’’ cells (and vice versa for tumors with low R values).
Statistical analysis. R14 and NCSS/PASS software were used. Reported
P values are two sided. ANOVA and t tests for gene expression data
were done using SAS. For clustering, we used CLUSTER and TREEVIEW
(University of Glasgow) softwares.
Results
MBCs possess patterns of DNA copy number gains and
losses that are distinct from those in common breast cancers.
MBCs showed a high level of genomic instability based on fraction
of the genome altered and number of transitions. However, MBCs
showed a unique set of aberrations compared with common breast
cancers (Fig. 1; refs. 13, 14). Specifically, gains of distal chromosome
1p/5p and loss of 3q were common in MBCs but rare in other
breast cancers (13, 14). Conversely, alterations that occur in most
breast cancers, such as gain of chromosome 1q and loss of 16q,
were uncommon in MBC (13, 14). In particular, compared with
basal-like tumors, MBCs exhibited more frequent amplification of
1p/11q/12q/14q/19p/19q/22q and increased frequency of loss at
1q/2p/3q/8q. There was retention of 5q/9q/15q/16p/17p/17q/19p/
19q/20q/22q compared with basal-like tumors. Overall, MBCs did
not display similar alterations to basal-like cancers and showed
substantial differences from common breast cancers, compatible
with MBCs representing a distinct subgroup.
MBCs possess distinct patterns of somatic mutations from
basal-like breast cancers. PIK3CA mutations were detected in
9 of 19 (47.4%) MBCs compared with 80 of 232 (34.5%) hor-
mone receptor-positive cancers (P = 0.32), 17 of 75 (22.7%) HER-2-
amplified samples (P = 0.04), 20 of 240 (8.3%) triple-negative
cancers (P < 0.0001), and 0 of 14 claudin-low tumors (P = 0.004;
Table 1; ref. 12). The PIK3CA mutation frequencies in the common
subtypes are compatible with those frequencies reported in the
literature, with the exception of that in claudin-low tumors, which
has not been reported (27). One PTEN mutation was detected in a
MBC (5%) that did not have a PIK3CA mutation. p53 mutations
were detected in 6 of 19 (32%) MBCs. No mutation in exon 3 of
CTNNB1 was detected in 19 MBCs.
Strikingly, therefore, 10 of 19 (53%) MBCs showed PI3K/AKT
pathway mutations. This was significantly different from the muta-
tion rate in triple-negative/basal-like cancers in particular. Fur-
ther, other PI3K/AKT pathway genomic aberrations were more
frequent in MBCs. Based on two SNP probes closest to each end
of genes encoding PI3K/AKT components, AKT1 (chromosome 14),
AKT2 (chromosome 19), and RPS6KB2 (p70S6K, chromosome 11)
showed more frequent copy number gain (Fisher’s exact test,
P < 0.05 at a 1% false discovery rate) in MBCs compared with other
subtypes. This was also supported at the protein level using reverse-
phase protein array data (Supplementary Table S2). Thus, PI3K/AKT
pathway aberrations likely play a major role in MBC pathophysiol-
ogy, further suggesting that MBCs and basal-like tumors are distinct.
PI3K pathway activation in MBC. The high frequency of
genomic aberrations in PI3K/AKT pathway genes implicates this
pathway in MBC pathogenesis. This pathway has already been
implicated in breast cancer resistance to multiple therapies (28–30).
Using reverse-phase protein array, phosphorylation of most core
PI3K/AKTpathway proteins was elevated inMBCs comparedwith at
least one other breast tumor subtype (Fig. 2), with the exception of
phosphorylated p70S6K. The most likely explanation for the latter
discrepancy is phosphorylation of p70S6K by kinases other than core
PI3K/AKT pathway kinases (31, 32). Overall, however, key PI3K/AKT
pathway components are generally more highly phosphorylated in
MBCs than in most other breast tumors, which parallels the results
of the genomic analyses and could contribute to the poor outcomes
associated with MBC (Supplementary Fig. S2).
Only glycogen synthase kinase 3 phosphorylation was higher
in MBCs possessing mutant versus wild-type PIK3CA/PTEN genes
(P = 0.01). The failure to show an association between PI3K/AKT
pathway mutations and activation is potentially due to the small
number of tumors analyzed. However, alterations in PI3K/AKT
pathway activation by processes independent of mutations, by
other interacting pathways, or by signaling modulation through
feedback loops may have prevented identification of statistically
significant associations (33). Compatible with the latter contention,
we have shown previously that PIK3CA mutational status is not
correlated with AKT phosphorylation in hormone receptor-positive
breast cancers or cell lines (12).
We also quantified expression and phosphorylation of several
PI3K/AKT pathway-activating and pathway-related proteins
Table 1. Frequency of mutations in the PIK3CA, AKT1/2/3, PTEN, and KRAS genes in human breast cancers
Tumor subtype PIK3CA catalytic
domain (%)
PIK3CA
other (%)
PIK3CA
total (%)
PTEN
(%)
AKT1
E17K (%)
AKT2/3
E17K (%)
KRAS (%)
All human breast tumors, excluding
metaplastic and claudin-low cancers
73/547 (13.3) 44/547 (8.0) 117/547 (21.4) 2/88 (2.3) 6/418 (1.4) 0/418 (0) 0/418 (0)
Human breast HR+ 48/232 (20.7) 32/232 (13.8) 80/232 (34.5) 2/58 (3.4) 6/232 (2.6) 0/232 (0) 0/232 (0)
Human breast HER-2+ 13/75 (17.3) 4/75 (5.3) 17/75 (22.7) 0/10 (0) 0/75 (0) 0/75 (0) 0/75 (0)
Human breast TN 12/240 (5.0) 8/240 (3.3) 20/240 (8.3) 0/20 (0) 0/111 (0) 0/111 (0) 0/111 (0)
Human breast claudin-low 0/14 (0) 0/14 (0) 0/14 (0) — 0/14 (0) 0/14 (0) 0/14 (0)
Human breast metaplastic 4/19 (21.1) 5/19 (26.3) 9/19 (47.4) 1/19 (5.3) 0/19 (0) 0/19 (0) 1/19 (5.3)
NOTE: PIK3CA, AKT1/2/3 , and PTEN mutation frequency in hormone receptor–positive (HR+), HER-2–positive, and triple-negative (TN) cancers, used
herein as a comparator for metaplastic and claudin-low tumors, has been published (12).
14 http://cran.r-project.org
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(Supplementary Table S2). Epidermal growth factor receptor
expression was lower in MBCs compared with other breast cancer
subtypes. HER-2 levels were also significantly decreased in MBCs
relative to hormone receptor-positive, triple-negative, and, in
particular, HER-2–positive tumors. Cyclin E1, a PI3K/AKT pathway
target, was present at higher levels in MBCs compared with
hormone receptor-positive and HER-2–positive tumors (P = 0.0005
and 0.02, respectively; refs. 34, 35). The Y box–binding protein 1
(YB1) has been implicated in chemoresistance and is located in the
chromosome 1p amplicon in MBC (Fig. 1; ref. 36). Indeed, YB1 was
more frequently amplified (at 1% false discovery rate) in MBCs than
in other tumors, and YB1 protein expression was also higher in
MBCs.
MBC transcriptional profiles are distinct from those of
basal-like breast cancers and related to those of claudin-low
breast tumors. On unsupervised hierarchical clustering, the
majority of MBCs displayed markedly different mRNA profiles
from those of most common breast cancers including basal-like
cancers (data not shown). To explore the relationships between
MBCs and the intrinsic breast cancer subtypes, 12 MDACC MBCs
were compared with 184 breast tumors and 9 normal breast
samples by hierarchical clustering using a combination of four
Figure 1. Gene copy number changes. Gains and losses in all common breast cancers (including luminal, HER-2–amplified, and basal-like cancers) and basal-like
cancers alone versus metaplastic breast tumors were determined. Chromosomes are subdivided into arms and ordered from left to right, beginning with 1p, 1q
and ending with X.
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intrinsic gene lists (8, 9, 15, 37). MBCs were somewhat
heterogeneous in this analysis (Supplementary Fig. S3). Two MBCs
clustered with basal-like tumors, two with a novel subtype of
receptor-negative tumors that is characterized by loss of a cluster
of genes that encode proteins involved in cell-cell adhesion
(claudin-low tumors), two clustered within the normal-like group,
and six formed a novel subgroup with characteristics intermediate
between those of basal-like and claudin-low tumors (Supplemen-
tary Fig. S3).
To assess the significance of this clustering pattern, we applied
‘‘SigClust’’ to test the null hypothesis that any group of samples
contained within a common dendrogram branch constitutes a
single group (38). This analysis showed that the dendrogram
branch containing six MBCs, along with some previously assayed
tumors, represents a distinct group. On reanalysis of the histology
of the latter tumors, four showed metaplastic and/or spindloid
features compatible with the tumors representing MBCs (Supple-
mentary Fig. S4). Further, mouse mammary tumors that are similar
to human claudin-low tumors show a spindloid morphology (9).
The gene set that defines claudin-low and MBC tumors
(Supplementary Fig. S3C) was determined by Gene Ontology
analysis to be enriched for the terms tight junction, intercellular
junction, apicolateral plasma membrane, and cell junction. Of 29
claudin-low cluster genes, 13 are positively regulated by GATA3 and
none by estrogen receptor-a (hypergeometic mean analysis,
P < 0.01; ref. 39). In addition to lacking genes involved in cell-cell
adhesion and polarity, MBCs and claudin-low tumors lack luminal
genes including GATA3 (Supplementary Fig. S3F) and HER-2 and
show inconsistent expression of genes associated with basal-like
tumors (Supplementary Fig. S3D). t tests confirmed that the
expression of the claudin-low cluster of genes (Supplementary
Fig. S3C) was lower in MBCs versus other breast cancers
(Supplementary Table S3).
MBCs and claudin-low tumors express high levels of stem
cell and EMT markers. SAM was used to identify a MBC versus
common breast tumor expression signature (40, 41). This analyses
resulted in 556 up and 373 down genes, with a false discovery rate
of <1 gene (Supplementary Table S4). Almost 33% of the ‘‘SAM up’’
and 50% of the SAM down genes mapped to regions of copy
number aberration (see below). In a Gene Ontology analysis using
Expression Analysis Systematic Explorer, the top six enriched
biological processes in the ‘‘up’’ gene list were cell communication,
Figure 2. Functional proteomics of MBC. Comparative expression of seven core PI3K/AKT pathway phosphoproteins in 383 hormone receptor–positive (HR ), 142
HER-2–positive (HER ), and 168 triple-negative (TN ) breast tumors and 16 MBCs was determined. GSK3, glycogen synthase kinase 3; XpY, phosphorylation of protein
X at amino acid(s) Y.
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cell adhesion, signal transduction, cellular process, cell-cell
adhesion, and intracellular protein transport, whereas protein
transport, intracellular transport, transport, male meiosis, and
ubiquitin-dependent protein catabolism were enriched in the
‘‘down’’ gene list (40). The claudin-low gene cluster showed a
statistically significant overlap with the SAM-defined ‘‘down’’ genes
(15 of 29 genes; hypergeometic mean analysis, P < 0.001). Genes
near the top of the MBC ‘‘up’’ list that have been previously
implicated in carcinogenesis included ALK , crystallin g, and the
master regulator of EMT, TWIST1 (42–45).
Breast cancers are thought to contain a minority population of
tumor initiating/stem cell-like cells with high CD44 but low or
undetectable levels of CD24 (CD44+/CD24); these cells have
higher ‘‘tumorigenic’’ capacity than other purified populations of
tumor-derived cells (46). Their phenotype and the low responsive-
ness of MBCs to chemotherapy suggest that MBCs might possess
stem cell-like characteristics. Indeed, MBCs had markedly elevated
CD44/CD24 and CD29/CD24 ratios compared with other breast
cancers, with the exception of claudin-low tumors (Fig. 3). This
‘‘electronic stem cell signature’’ is also differentially expressed
between fluorescence-activated cell-sorted human breast tumor-
initiating cells and normal breast epithelial cells (Supplementary
Fig. S5; refs. 46, 47).
EMT is characterized by the up-regulation of vimentin and of E-
cadherin repressor molecules (snail/slug/twist) with down-regula-
tion of E-cadherin and other cell adhesion molecules (45, 48, 49).
These events occur in MBCs and claudin-low tumors (Fig. 3;
Supplementary Table S3). In MBCs, TWIST1 and snail homologue 2
(SNAI2/SLUG) were expressed at high levels, whereas SNAI3 was
overexpressed in claudin-low tumors. Thus, claudin-low tumors
and MBCs may be enriched for stem cell-like and EMT markers,
features that may contribute to poor patient outcomes (Supple-
mentary Fig. S2; refs. 2, 3).
Genes that are altered at the genomic and transcriptional
levels in MBC. Three hundred six genes (Supplementary Table S5)
in the SAM-derived MBC transcriptome localized to areas of
chromosomal gain and loss in at least 33% of MBCs (Supplemen-
tary Fig. S6A and B). Thus, these genes show coordinate changes at
the DNA and RNA levels in MBC. Functional analysis of these genes
(Supplementary Tables S6 and S7) showed that, among genes that
are amplified and overexpressed in MBCs, components of three
major branches (JNK, MAPK, and p38) that compose the MAPK
signaling pathway are significantly overrepresented in MBCs.
Compatible with this finding, phosphorylation of three of four
assessed protein components of these pathways [JNK (P = 0.06),
MEK (P = 0.003), and p38 (P = 0.0008) but not ERK1/2 (P = NS)]
was higher in MBCs versus all other breast cancers.
Comparison of the MBC and claudin-low transcriptional
profiles with a CD44+/CD24/low breast cancer cell profile.
Given their enrichment for stem cell markers, we compared the
transcriptional signatures of MBCs and other breast cancers with a
‘‘tumorigenic’’ signature13 that was derived by comparing gene
expression profiles of flow-sorted CD44+/CD24/low breast tumor
cells with profiles of all other sorted cells (CD44/CD24+ and
CD44/CD24). In contrast to other breast cancers, except for
tumors of the ‘‘claudin-low’’ subtype, most of the MBCs showed a
clear association with the ‘‘tumorigenic’’ signature (Fig. 4). Further,
of 373 and 217 down-regulated genes in the MBC and ‘‘tumori-
genic’’ signatures, respectively, there were 29 shared genes
(Supplementary Table S8; P = 1  10-13 for the overlap); 5 of these
29 genes were components of the claudin-low gene cluster. In
Figure 3. Expression of claudin-low and stem cell markers in breast cancer
subgroups. Using data from transcriptional profiling, metaplastic (Metap) and
claudin-low tumors express low levels of claudins CLDN3, CLDN4, and CLDN7
of CDH1 (E-cadherin) and high CD44/CD24 and CD29/CD24 ratios. P values
(ANOVA). P values for the metaplastic-basal comparison of stem cell markers
were 0.41 (BMI1), 0.19 (CD44), 0.004 (CD29), 0.00009 (CD24), 0.00006 (CD44/
CD24 ratio), and 0.00007 (CD29/CD24 ratio).
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addition, as has been shown with the claudin-low signature,13 the
MBC signature is enriched in post-docetaxel and post-letrozole
treatment specimens (Supplementary Fig. S7). These data collec-
tively suggest that, at diagnosis, MBCs and claudin-low tumors
possess transcriptional features that are enriched in highly purified
breast tumor-initiating and chemoresistant breast cancer cell
fractions (50), the latter also compatible with an enrichment for
stem cell-like activity.
Discussion
MBCs are aggressive, chemoresistant tumors associated with poor
outcomes (2, 3). Although uncommon, MBCs account for several
hundred new breast cancer cases every year in the United States,
thus representing a therapeutic dilemma for oncologists. With only
retrospective case reviews as a basis for making recommenda-
tions, it has not been possible to define therapy guidelines. Thus,
we sought to determine the relationship of MBCs to common breast
cancers, particularly basal-like breast cancers given the common
assumption that MBCs are basal-like cancers. We also sought to
determine whether the underlying pathophysiology of MBCs would
result in the identification of new drug targets.
Supplementary Fig. S8 summarizes the features of MBC defined
in this study that have potential clinical and therapeutic utility.
Due to low expression of hormone receptors and HER-2 as well as
expression of some basal epithelial markers, MBCs have been pro-
posed to represent a form of basal-like breast cancer (4). How-
ever, based on the integrated analyses herein, most MBCs likely
represent an independent subtype that is distinct from basal-like
cancers. Their transcriptional profiles are most closely related to
claudin-low cancers, a novel subgroup of receptor-negative breast
cancers that are clearly different from basal-like cancers (Supple-
mentary Fig. S3). Comparative genomic hybridization profiles,
their enrichment for stem cell-like markers, and their PI3K/AKT
pathway activation status also differentiate MBCs from basal-like
cancers. MBCs, like claudin-low cancers, express high levels of EMT
markers and show elevated CD44/CD24 and CD29/CD24 ratios,
which have been proposed to represent breast cancer stem cell-like
markers (46). Indeed, a recent study detected a direct and causative
link between EMT and the gain of epithelial stem cell properties
(51). These features likely contribute to the lineage plasticity of
MBCs on light microscopy and to their limited chemoresponsive-
ness (2, 3). Claudin-low features, including EMT and stem cell-like
properties, also potentially contribute to the aggressive phenotype
of MBCs. This is supported by the significant overlap between the
MBC signature and the ‘‘tumorigenic’’ signature,13 with overlapping
genes including five of the claudin-low genes (Supplementary
Fig. S3C). The MBC, the ‘‘tumorigenic,’’ and the claudin-low
signatures are all enriched in residual post-treatment chemo-
resistant breast tumors. Thus, MBCs and claudin-low breast tumors
may arise from a more primitive and chemoresistant ‘‘stem’’ cell
than luminal or basal-like tumors.
The pattern of chromosomal gains and losses in MBCs is distinct
from that in other breast cancers including basal-like cancers. This
unique pattern suggests that the processes underlying metaplastic
carcinogenesis are distinct from those associated with other breast
cancer subtypes. MBCs show a high frequency of mutation,
amplification, and activation of PI3K/AKT pathway components.
This is markedly different from basal-like breast cancers, where we
and others have shown that PI3K/AKT pathway genomic
mutations are uncommon (12, 27).15 We also did not detect
PIK3CA mutations in 14 claudin-low breast cancers pointing to
differences between claudin-low breast cancers and MBCs. The
frequency of PIK3CA and PTEN mutations combined with
amplification of AKT and p70S6K suggests that PI3K/AKT pathway
activation is critical to metaplastic carcinogenesis. Activation of
this pathway, along with enrichment for tumor-initiating/stem
cells, may underlie the chemoresistance and poor outcomes
associated with MBC (28–30). MBCs also show a high frequency
of amplification, overexpression, and activation of MAPK pathway
components. As particularly important genes and targets in cancer
are likely to be aberrant at the level of the genome, transcriptome,
and proteome, the PI3K/AKT and MAPK pathways are therefore
Figure 4. A CD44+/CD24-/low ‘‘tumorigenic’’ gene signature is enriched in human breast tumors of the ‘‘claudin-low’’ and metaplastic (MBC) subtypes. The correlation
shown is between the ‘‘tumorigenic’’ signature pattern (Creighton and colleagues, submitted for publication; using ‘‘1’’ and ‘‘-1,’’ for up and down genes, respectively) and each
MBC as well an each tumor in the gene expression profile dataset by Herschkowitz and colleagues (9). R values above red dotted line are significant (P < 0.00001).
15 www.sanger.ac.uk
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potentially attractive therapy targets in MBC. As inhibitors of the
PI3K/AKT and MAPK pathways are now in clinical trials, it will be
of interest to determine whether these inhibitors will sensitize
MBCs to cytotoxic drugs (52). As there are no MBC cell lines or
animal models available, it will be necessary to develop a con-
sortium approach to test this hypothesis in patients.
In contrast to a recently published study, mutations in exon 3
of CTNNB1 were not identified in 19 MBCs in our study (53).
This may in part relate to the fact that our study was restricted to
high-grade MBCs, whereas the previous study included a significant
proportion of lower-grade MBCs, tumors that behave in a less
aggressive fashion than high-grade MBCs.
This study has several potential limitations. Although a subset
(6 of 12, 50%) of MBCs constitute a significantly related group of
tumors as defined by SigClust, it is clear that MBCs form a
somewhat heterogeneous group of receptor-negative breast
cancers in terms of their molecular characteristics. Just as breast
tumors that are defined as ductal are clearly heterogeneous based
on receptor status and transcriptional profiling, it is not surpris-
ing that MBCs represent a molecularly heterogeneous group.
MBCs are microscopically heterogeneous, with this study being
limited to tumors with squamous and sarcomatoid metaplasia
(1–7). The rarity of MBC precluded analysis of other histologic
variants. In addition, it is possible that MBC represents multiple
different diseases. However, there were no clear correlation
between the pattern of gene copy number change and the
histologic appearance of the tumors analyzed.
The major conclusions of this article are (a) MBCs are
molecularly distinct from other breast cancers; (b) despite their
relative histologic uniformity, MBCs are molecularly heteroge-
neous; and (c) claudin-low breast cancers are likely the most
closely related ductal breast cancer subset to MBCs. The molecular
mechanisms underlying metaplastic carcinogenesis are likely
different from those associated with other breast cancer subtypes
including basal-like cancers. By gene expression analysis, MBCs
and claudin-low tumors share common features that suggest
related cellular origins, potentially from a more primitive cell than
that implicated as a precursor to luminal or basal-like tumors.
It is likely that MBCs, and potentially claudin-low tumors, define a
novel chemoresistant triple-negative breast cancer subgroup that
exhibits a signature similar to that of breast tumor-initiating
cells and of residual common breast tumor cells isolated after
patient treatment. The frequency of PI3K/AKT pathway aberrations
argues that this pathway should be explored as a therapeutic target
in MBC. A challenge to advancing therapy for MBC patients is the
infrequency of this disease. However, a centralized clinical trial
effort is a feasible venture that will improve patient outcomes.
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